Regulatory Considerations for Moving from Emergency Use Authorization to Biological License Application for U.S. Products
Speaker Presentation Levis Robin CBER FDA 2022
Regulatory Considerations for Moving from Emergency Use Authorization to Biological License Application for U.S. Products